Clinical Trial Update: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma. [Phase 2]

View source ↗

Summary

A Phase II study evaluated the efficacy, safety, and tolerability of AZD5069 in patients with uncontrolled persistent asthma; the trial has completed and result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• AZD5069 (CXCR2 inhibitor)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 2 | Status: COMPLETED | Results posted: 2016-03-01